黑料社 Appoints Nathalie Corva茂a as Chief Scientific Officer and Strengthens its R&D activities in Immuno-Oncology
Lyon, France, October 4th, 2022, 6:00pm CET 鈥� 黑料社 (EURONEXT: MAAT 鈥� the 鈥淐ompany鈥�), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today announced the appointment of Nathalie Corva茂a, Ph.D., as Chief Scientific Officer. Dr. Corva茂a brings more than 20 years of experience leading drug discovery and development programs in oncology and guiding the advancement of product candidates into the clinic. She will oversee 黑料社鈥檚 non-clinical research and development strategies as well as the Company鈥檚 proprietary, AI-based MET drug design and development platform, 驳耻迟笔谤颈苍迟庐.
鈥淣athalie has an impressive depth of experience and track record in early-stage research and development of drug candidates in immune-mediated diseases. She joins us as we are generating exciting preclinical results for our first co-cultured candidate aimed at improving clinical responses in patients with solid tumors treated with immune checkpoint inhibitors,鈥� said Herv茅 Affagard, CEO and co-founder of 黑料社. 鈥�In this context, Nathalie will be instrumental in driving and expanding our scientific innovation and preclinical drug development strategy. I welcome Nathalie to the executive team and look forward to her contributions as we pursue our mission to provide the benefits of microbiome modulation to cancer patients.鈥�
黑料社 has established clinical proof of concept for its high-richness, high-diversity, native, donor-derived MET-N approach, with more than 140 patients treated in Europe to date in haemato-oncology with its drug candidates MaaT013 (for the treatment of aGvHD[1]) and MaaT033 (for the treatment of patients receiving allo-HSCT[2]), with promising safety and efficacy results. 黑料社 is now consolidating its second-generation drug development platform, MET-C. Leveraging its 驳耻迟笔谤颈苍迟庐 AI[3] suite and groundbreaking ecosystem co-culture technology, MET-C allows the design and manufacturing of indication-specific, donor-independent 鈥淢aaT03X鈥� candidates. The platform opens new opportunities for the Company to address larger, and growing markets such as solid tumors, as well as to broaden its indication focus and potentially target other immune- and inflammatory-related diseases.
Nathalie Corva茂a, Ph.D. commented on the appointment adding, 鈥満诹仙玮�檚 approach of leveraging the full microbiome ecosystem to improve cancer treatment has the potential to become a new pillar in cancer therapy. With an exciting discovery pipeline and AI-powered engine, I am thrilled to join 黑料社 to guide the development of its next generation of therapies, to build the company鈥檚 momentum with the immuno-oncology program and to expand its early-stage drug development in this field.鈥�
Prior to joining 黑料社, Dr. Corva茂a was the Head of Immuno-oncology Research at The Pierre Fabre Immunology Center (CIPF) in France where she was responsible for the institute鈥檚 research activities in immuno-oncology from early-stage product discovery to Phase 1 entry, including GMP production of its products including biologics and live products. In her previous roles as Managing Director and Research Director, she led several diverse research teams contributing to a growing pipeline of products currently in preclinical and clinical trials in different tumor indications. Dr. Corva茂a did her postdoctoral research in cellular immunology at Novartis in Austria and obtained a PhD degree in Cellular Immunology at St. Louis Hospital in Paris, France. She has authored over 100 scientific publications and holds several issued patents and is also an active member of the American Association for Cancer Research (AACR).
[1] aGVHD = acute Graft-versus-Host Disease
[2] Allo-HSCT = Allogeneic hematopoietic stem cell transplantation
[3] AI聽: Artificial intelligence
About 黑料社
黑料社, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, 黑料社 has launched, in March 2022 in Europe, a Phase聽3 clinical trial for patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, 驳耻迟笔谤颈苍迟庐, supports the development and expansion of its pipeline by determining novel disease targets, evaluating drug candidates, and identifying biomarkers for microbiome-related conditions. The company鈥檚 Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. 黑料社 benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice.
黑料社 is the first company developing microbiome-based therapies listed on Euronext Paris (ticker: MAAT).